Dr. Joseph R. Moore, M.D.
Pediatrics (Pediatrics Physician)
Who else practices at this address →
Bonneville County includes primary care (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
ID license M-9074
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $16.12 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.12 |
|---|
| Food and Beverage | $16.12 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 4 companies. The companies reported $1,318,307 in research payments for these studies, mostly to the institutions running them.
- Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06252285 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company · Active, not recruiting · NCT04616326 - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396574 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company · Active, not recruiting · NCT03432286 - A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396236 - A phase 3A, observer-blind, randomized, controlled study to demonstrat
GlaxoSmithKline, LLC. - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956 - Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06736041 - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.